Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Valneva SE

Market Cap 43Cr 50Cr 40Cr 37Cr 70Cr 4.74TCr 71Cr 470.29Cr 183.21Cr 2.32TCr 188.21Cr 184.22Cr 8.05TCr P/E 2026 *
-6.21x
P/E 2027 * 6x
Enterprise Value 56Cr 65Cr 52Cr 48Cr 91Cr 6.15TCr 92Cr 609.58Cr 237.48Cr 3.01TCr 243.96Cr 238.78Cr 10TCr EV / Sales 2026 *
3.69x
EV / Sales 2027 * 1.67x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day+2.19%
1 week+3.70%
Current month-10.83%
1 month-5.59%
3 months-50.70%
6 months-34.51%
Current year-37.36%
1 week 2.18
Extreme 2.182
2.37
1 month 2.18
Extreme 2.182
2.72
Current year 2.14
Extreme 2.135
5.15
1 year 2.14
Extreme 2.135
5.42
3 years 1.73
Extreme 1.726
7.85
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap.
27/01Sell

Chief Technology Officer

11,800 0.0069%
26/01Sell

Chief Financial Officer

11,800 0.0069%
19/01Fiscal year

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%+3.70%-6.77%-65.67% 50Cr
-0.22%-1.14%-11.88%-10.15% 4.35TCr
+2.44%+11.15%+309.48%+524.10% 3.33TCr
+0.49%+1.05%+4.84%+39.05% 2.93TCr
-3.32%-5.12%+12.17%-19.58% 2.99TCr
+0.06%+2.71%+13.31%+21.11% 2.54TCr
+0.38%+11.28% - - 1.44TCr
+0.75%-0.60%+55.38%+105.48% 1.32TCr
-0.29%-4.40%+3.13%+4.23% 1.27TCr
+2.82%+2.25%+107.38%+82.54% 1.21TCr
Average +0.51%+0.62%+54.12%+75.68% 2.14TCr
Weighted average by Cap. +0.12%+0.72%+63.48%+102.58%

Financials

2026 *2027 *
Net sales 15Cr 18Cr 14Cr 13Cr 25Cr 1.67TCr 25Cr 165.2Cr 64Cr 815.64Cr 66Cr 65Cr 2.83TCr 29Cr 34Cr 27Cr 25Cr 48Cr 3.23TCr 48Cr 319.95Cr 124.64Cr 1.58TCr 128.04Cr 125.33Cr 5.47TCr
Net income -6.6Cr -7.66Cr -6.08Cr -5.71Cr -11Cr -724.22Cr -11Cr -72Cr -28Cr -354.65Cr -29Cr -28Cr -1.23TCr 7.05Cr 8.18Cr 6.49Cr 6.1Cr 11Cr 773.45Cr 12Cr 77Cr 30Cr 378.76Cr 31Cr 30Cr 1.31TCr
Net Debt 13Cr 15Cr 12Cr 11Cr 21Cr 1.4TCr 21Cr 139.29Cr 54Cr 687.74Cr 56Cr 55Cr 2.38TCr 6Cr 6.96Cr 5.53Cr 5.19Cr 9.74Cr 658.43Cr 9.85Cr 65Cr 25Cr 322.44Cr 26Cr 26Cr 1.12TCr
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
17/26/17 2.329 +2.19% 3,83,317
16/26/16 2.279 -0.57% 4,12,911
15/26/15 2.292 +0.26% 3,36,120
12/26/12 2.286 +3.25% 3,52,774
11/26/11 2.214 -1.42% 5,83,232
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.279EUR
Average target price
5.233EUR
Spread / Average Target
+129.63%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!